

NDA 019658/S-064

SUPPLEMENT APPROVAL

Bayer HealthCare LLC
Attention: Amrita Raman
Associate Director, US Regulatory Affairs
100 Bayer Boulevard
Whippany, NJ 07981-0915

Dear Amrita Raman:¹

Please refer to your supplemental new drug application (sNDA) dated and received April 3, 2026, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Claritin Hives Relief (loratadine) oral tablet, 10 mg.

This “Prior Approval” supplemental new drug application provides for revisions to the carton and blister card labeling, along with the removal of the currently approved package insert.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below.

Submitted Draft Labeling	Date submitted
30-count outer carton	7/30/2026
10-count immediate container (blister card)	4/3/2026

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The FPL should be submitted electronically according to guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.² For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 019658/S-064.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.³ Information on submitting SPL files using eLIST may be found in guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, contact Tam Dinh, PharmD, Regulatory Project Manager, at 240-402-6284 or Tam.Dinh@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Ovidiu Galescu, MD
Deputy Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton and Blister Card Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

OVIDIU A GALESCU
09/25/2026 10:02:11 AM